Mitochondrial function and NMDA receptor activation: Mechanisms of secondary excitotoxicity

Functional Neurology

Volumn 14, Issue 3, 1999, Pages 171-184

  Greene, James G ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Calcium; Excitotoxicity; Glutamate; Mitochondria; NMDA

Indexed keywords

ADENOSINE TRIPHOSPHATE; CALCIUM ION; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; REACTIVE OXYGEN METABOLITE;

ALZHEIMER DISEASE; CALCIUM HOMEOSTASIS; DEGENERATIVE DISEASE; ENERGY METABOLISM; HUMAN; HUNTINGTON CHOREA; MITOCHONDRION; REVIEW;

ANIMALS; CALCIUM; CELL DEATH; ENERGY METABOLISM; GLUTAMIC ACID; HUMANS; MITOCHONDRIA; NEURODEGENERATIVE DISEASES; NEURONS; NEUROTOXINS; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 0032764506     PISSN: 03935264     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Beal MF. Mitochondrial dysfunction in neurodegenerative diseases. Biochim Biophys Acta 1998;1366:211-223
2. Murphy AN, Fiskum G, Beal MF. Mitochondria in neurodegeneration: bioenergetic function in cell life and death. J Cereb Blood Flow Metab 1999;19:231-245
3. Fiskum G, Murphy AN, Beal MF. Mitochondria in neurodegeneration: acute ischemia and chronic neurodegenerative diseases. J Cereb Blood Flow Metab 1999; 19:351-369
4. Nicotera P, Lipton S. Excitotoxins in neuronal apoptosis and necrosis. J Cereb Blood Flow Metab 1999;19:583-591
5. Tatton WG, Olanow CW. Apoptosis in neurodegenerative diseases: the role of mitochondria. Biochim Biophys Acta 1999; 1410:195-213.
6. Greene JG, Greenamyre JT. Bioenergetics and glutamate excitotoxicity. Prog Neurobiol 1996;48:613-634
7. Gunter TE, Gunter KK, Sheu SS, Gavin CE. Mitochondrial calcium transport. Am J Physiol 1994;267:C313-C339
8. Ichas F, Mazat J-P. From calcium signaling to cell death: two conformations for the mitochondrial permeability transition pore. Biochim Biophys Acta 1998;1366: 33-50
9. Bernardi P, Broekemeier KM, Pfeiffer DR. Recent progress on the regulation of the mitochondrial permeability transition pore: a cyclosporin-sensitive pore in the inner mitochondrial membrane. J Bioenerg Biomembr 1994;26:509-517
10. Bowling AC, Beal MF. Bioenergetic and oxidative stress in neurodegenerative diseases. Life Sci 1995;56:1151-1171
11. Beal MF. Aging, energy and oxidative stress in neurodegenerative diseases. Ann Neurol 1995;38:357-366
12. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 1997;42:85-94
13. Kennedy AM, Frackowiak RSJ, Newman SK et al. Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer's disease. Neurosci Lett 1995;186:17-20
14. Swerdlow RH, Parks JK, Cassarino DS et al. Cybrids in Alzheimer's disease: a cellular model of the disease? Neurology 1997;49:918-925
15. Sheehan JP, Swerdlow RH, Miller SW et al. Calcium homeostasis and reactive oxygen species production in cells transformed by mitochondria from individuals with sporadic Alzheimer's disease. J Neurosci 1997;17:4612-4622
16. Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1989;i:1269 (letter)
17. Schapira AHV, Mann VM, Cooper JM. Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J Neurochem 1990b;55:2142-2145
18. Parker WD, Boyson SJ, Parks JK. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol 1989;26:719-723
19. Swerdlow RH, Parks JK, Davis JN et al. Matrilineal inheritance of complex I dysfunction I in a multigenerational Parkinson's disease family. Ann Neurol 1998;44: 873-881
20. Sheehan JP, Swerdlow RH, Parker WD, Miller SW, Davis RE, Turtle JB. Altered calcium homeostasis in cells transformed by mitochondria from individuals with Parkinson's disease. J Neurochem 1997; 68:1221-1233
21. Mazziotta JC, Phelps ME, Pahl JI. Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease. N Engl J Med 1987;316: 356-362
22. 18FDG and computed tomographic scan. Ann Neurol 1982;12: 425-434
23. Jenkins BG, Rosas HD, Chen YC et al. 1H NMR spectroscopy studies of Huntington's disease: correlations with CAG repeat numbers. Neurology 1998;50:1357-1365
24. Gutekunst C-A, Peng T-I, Whalet WL, Rock B, Hersch SM, Greenamyre JT. Mitochondrial calcium homeostasis in Huntington's disease fibroblasts. Society for Neuroscience Abstracts 1996;22:227
25. Browne SE, Ferrante RJ, Beal MF. Oxidative stress in Huntington's disease. Brain Pathology 1999;9:147-163
26. Beal MF, Brouillet E, Jenkins BG, et al. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial inhibitor 3-nitropropionic acid. J Neurosci 1993;13:4181-4192
27. Brouillet E, Hantraye P, Ferrante RJ et al. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc Nat Acad Sci USA 1995; 92:7105-7109
28. Beal MF, Kowall NW, Ellison DW, Mazurek MF, Swartz KJ, Martin JB. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 1986;321:168-172
29. Turski L, Bressler K, Rettig KJ, Loschmann PA, Wachtel H. Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists. Nature 1991;349:414-418
30. Zuddas A, Oberto G, Vaglini F, Fascetti F, Fornai F, Corsini GU. MK-801 prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in primates. J Neurochem 1992;59:733-739
31. Arias C, Becerra-Garica F, Tapia R. Glutamic acid and Alzheimer's disease. Neurobiol (Budapest) 1998;6:33-43
32. Pearson RC, Esiri MM, Hiorns RW, Wilcock GK, Powell TPS. Anatomical correlates of the distribution of the pathological changes in Alzheimer's disease. Proc Natl Acad Sci USA 1985;82:4531-4534
33. Greenamyre JT, Penney JB, Young AB, D'Amato CJ, Hicks SP, Shoulson I. Alterations in L-glutamate binding in Alzheimer's and Huntington's diseases. Science 1986;227:1496-1499
34. De Boni U, Crapper-McLachlan DR. Controlled induction of paired helical filaments of the Alzheimer's type in cultured human neurons, by glutamate and aspartate. J Neurol Sci 1985;68:105-118
35. 2+ influx in cultured hippocampal neurons. Neuron 1990;4:105-117
36. Cheng B, Mattson MP. Glucose deprivation elicits neurofibrillary tangle-like antigenie changes in hippocampal neurons: prevention by NGF and bFGF. Exp Neurol 1992;117:114-123
37. Koh J-Y, Yang LL, Cotman CW. ß-amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage. Brain Res 1990;533:315-320
38. Mattson MP, Cheng B, Davis D, Bryant K, Lieberburg I, Rydel RE. ß-amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci 1992;12:376-389
39. Sanchez-Carbente MR, Massieu L. Transient inhibition of glutamate uptake in vivo induces neurodegeneration when energy metabolism is impaired. J Neurochem 1999;72:129-138
40. Novelli A, Reilly JA, Lysko PG, Henneberry RC. Glutamate becomes neurotoxic via the NMDA receptor when intracellular energy levels are reduced. Brain Res 1988;451:205-212
41. Zeevalk GD, Derr-Yellin E, Nicklas WJ. NMDA receptor involvement in toxicity to dopamine neurons in vitro caused by the succinate dehydrogenase inhibitor 3-nitropropionic acid. J Neurochem 1995; 64: 455-458
42. Beal MF, Brouillet E, Jenkins BG, Henshaw R, Rosen B, Hyman BT. Age-dependent striatal lesions produced by the endogenous mitochondrial inhibitor malonate. J Neurochem 1993;61:1147-1150
43. Greene JG, Porter RHP, Eller RV, Greenamyre JT. Inhibition of succinate dehydrogenase by malonic acid produces an "excitotoxic" lesion in rat striatum. J Neurochem 1993;61:1151-1154
44. Brouillet E, Hyman BT, Jenkins BG et al. Systemic or local administration of azide produces striatal lesions by an energy impairment-induced excitotoxic mechanism. Exp Neurol 1994;129:175-182
45. Matthews RT, Ferrante RJ, Jenkins BG, et al. Iodoacetate produces striatal excitotoxic lesions. J Neurochem 1997;69:285-289
46. Henneberry RC. Excitotoxicity as a consequence of impairment of energy metabolism: the energy-linked excitotoxic hypothesis. In: Mitochondria and Free Radicals in Neurodegenerative Diseases. New York; John Wiley and Sons 1997:111-143
47. + transport in canine brain. Stroke 1981;12:726-730
48. Mata M, Fink DJ, Gainer H et al. Activity-dependent energy metabolism in rat posterior pituitary primarily reflects sodium pump activity. J Neurochem 1980;34:213-215
49. Erecínska M, Dagani F. Relationships between the neuronal sodium/potassium pump and energy metabolism. J Gen Physiol 1990;95:591-616
50. Nowak L, Bregestovski P, Ascher P, Herbet A, Prochiantz A. Magnesium gates glutamate-activated channels in mouse central neurones. Nature 1984:307:462-465
51. Zeevalk GD, Nicklas WJ. Mechanisms underlying initiation of excitotoxicity associated with metabolic inhibition. J Pharmacol Exp Ther 1991;257:870-878
52. 2+ block at the N-methyl-D-aspartate receptor underlies receptor activation during inhibition of neuronal metabolism. J Neurochem 1992;59:1211-1220
53. Greene JG, Sheu S-S, Gross RA, Greenamyre JT. 3-Nitropropionic acid exacerbates N-methyl-D-aspartate toxicity in striatal culture by multiple mechanisms. Neuroscience 1998;84:503-510
54. Greene JG, Greenamyre JT. Manipulation of membrane potential modulates malonate-induced striatal excitotoxicity in vivo. J Neurochem 1996;66:637-643
55. Blaustein MP, Goldman WF, Fontana G et al. Physiological roles of the sodium-calcium exchanger in nerve and muscle. Ann NY Acad Sci 1991;639:254-275
56. 2+ extrusion in protection against neuronal excitotoxicity. FASEB J 1989;3:2519-2526
57. 2+ exchange enhances delayed neuronal death elicited by glutamate in cerebellar granule cell cultures. Brain Res 1991;548:322-325
58. 2+ exchange buffer glutamate-induced calcium loads in cultured cortical neurons. J Neurosci 1995;15:1318-1328
59. Kiedrowski L, Brooker G, Costa E, Wroblewski JT. Glutamate impairs neuronal calcium extrusion while reducing sodium gradient. Neuron 1994;12:295-300
60. Rothman SM. Excitotoxins: possible mechanisms of action. Ann NY Acad Sci 1992;648:132-139
61. 2+ after toxic NMDA-receptor activity. J Neurochem 1995;65:739-743
62. Kiedrowski L, Costa E. Glutamate-induced destabilization of intracellular calcium concentration homeostasis in cultured cerebellar granule cells: role of mitochondria in calcium buffering. Mol Pharmacol 1995;47:140-147
63. White RJ, Reynolds IJ. Mitochondrial depolarization in glutamate-stimulated neurons: an early signal specific to excitotoxin exposure. J Neurosci 1996;16:5688-5697
64. Peng T-I, Greenamyre JT. Privileged access to mitochondria of calcium influx through N-methyl-D-aspartate receptors. Mol Pharmacol 1998;53:974-980
65. Coyle JT, Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science 1993;262:689-695
66. Beal MF. Excitotoxicity and nitric oxide in Parkinson's disease pathogenesis. Ann Neurol 1998;44 (3 Suppl 1): S110-114
67. Stout AK, Raphael HM, Kanterewicz BI, Klann E, Reynolds IJ. Glutamate-induced neuron death requires mitochondrial calcium uptake. Nature Neuroscience 1998; 1:366-373
68. Budd SL, Nicholls DG. Mitochondria, calcium regulation, and acute glutamate excitotoxicity in cultured cerebellar granule cells. J Neurochem 1996;67:2282-2291
69. 2+ accumulation in cortical cell culture correlates with subsequent neurode-generation. J Neurosci 1993;13:1993-2000
70. Dugan LL, Sensi SL, Canzoniero LMT et al. Mitochondrial production of reactive oxygen species in cortical neurons following exposure to N-methyl-D-aspartate. J Neurosci 1995;15:6377-6388
71. Trotti D, Danbolt NC, Volterra A. Glutamate transporters are oxidant-vulnerable: a molecular link between oxidative and excitotoxic neurodegeneration? Trends Pharmacol Sci 1998;19:328-334
72. Aizenman E, Hartnett KA, Reynolds IJ. Oxygen free radicals regulate NMDA receptor function via a redox modulatory site. Neuron 1990;5:841-846
73. Dykens JA, Stern A, Trenkner E. Mechanisms of kainate toxicity to cerebellar neurons in vitro is analogous to reperfusion tissue injury. J Neurochem 1987;49:1222-1228
74. Schulz JB, Henshaw DR, Siwek D et al. Involvement of free radicals in excitotoxicity in vivo. J Neurochem 1995b;63:2239-2247
75. Beal MF, Ferrante RJ, Henshaw R et al. 3-Nitropropionic acid neurotoxicity is attenuated in copper/zinc superoxide dismutase transgenic mice. J Neurochem 1995;65: 919-922
76. Matthews RT, Yang L, Browne S, Baik M, Beal MF. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc Nat Acad Sci USA 1998;95:8892-8897
77. Greenamyre JT, Garcia-Osuna M, Greene JG. The endogenous cofactors, thioctic acid and dihydrolipoic acid, are neuroprotective against NMDA and malonic acid lesions of striatum. Neurosci Lett 1994; 171:17-20
78. Sriram K, Shankar SK, Boyd MR, Ravindranath V. Thiol oxidation and loss of mitochondrial complex I precede excitatory amino acid-mediated neurodegeneration. J Neurosci 1998;18:10287-10296
79. Matthews RT, Yang L, Jenkins BG, et al. Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. J Neurosci 1998;18:156-163
80. Cassarino DS, Swerdlow RH, Parks JK, Parker WD, Bennett JP. Cyclosporin A increases resting mitochondrial membrane potential in SY5Y cells and reverses the depressed mitochondrial membrane potential of Alzheimer's disease cybrids. Biochem Biophys Res Commun 1998;248: 168-173
81. Seaton TA, Cooper JM, Schapira AH. Free radical scavengers protect dopaminergic cell lines from apoptosis induced by complex I inhibitors. Brain Res 1997;777:110-118
82. Yang L, Matthews RT, Schulz, JB et al. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyride neurotoxicity is attenuated in mice overexpressing Bcl-2. J Neurosci 1998;18:8145-8152
83. Chen RW, Chuang DM. Long term lithium suppresses p53 and Bax expression but increases Bcl-2 expression: a prominent role in neuroprotection against excitotoxicity. J Biol Chem 1999;274:6039-6042